Weisswange A, Csapo G, Kalusche D, Keck M
Acta Med Scand Suppl. 1982;659:123-36. doi: 10.1111/j.0954-6820.1982.tb00841.x.
Electrophysiological studies with prenalterol in 19 patients (6 women, 13 men, 5 with sinus node disease, 4 with AV node disease, 7 with double node disease, 2 with conduction disturbance below His bundle, 1 normal) showed that sinus node function (heart rate, sinus node recovery time) is uniformly improved by this beta-stimulator. Also AV conduction is significantly and uniformly improved (shortening of AH interval and of the functional refractory period of AV conduction). There is no or little influence on intra-atrial conduction and on conduction below the His bundle. However, spontaneous depolarisation in His-Purkinje fibers--as tested in patients with complete AV block and ventricular demand pacemaker--is increased through beta-stimulation with prenalterol as reflected by shorter escape intervals and higher frequency escape rhythm. Prenalterol may be of clinical use in patients with cardiomyopathies who developed bradycardia under digitalisation or patients with severe bradyarrhythmia either with or without digitalis. It might also be useful in rare emergency situations, when complete pacemaker failure develops.
对19例患者(6名女性,13名男性,5例窦房结疾病,4例房室结疾病,7例双结疾病,2例希氏束以下传导障碍,1例正常)使用普瑞特罗进行电生理研究,结果显示该β受体激动剂可使窦房结功能(心率、窦房结恢复时间)均得到改善。房室传导也显著且均一地得到改善(AH间期及房室传导功能不应期缩短)。对房内传导及希氏束以下传导无影响或影响很小。然而,在完全性房室传导阻滞并使用心室按需起搏器的患者中进行测试时,普瑞特罗的β刺激会使希氏-浦肯野纤维的自发去极化增加,表现为逸搏间期缩短及逸搏心律频率增加。普瑞特罗可能对在洋地黄化过程中出现心动过缓的心肌病患者或伴有或不伴有洋地黄的严重缓慢性心律失常患者有临床应用价值。在起搏器完全失效的罕见紧急情况下,它可能也有用。